07:43 AM EDT, 10/16/2026 (MT Newswires) -- Novo (NOVO-B.CO) received a positive opinion from the European Medicines Agency's human medicines committee on a proposed change in the indications of its type 2 diabetes drug Kyinsu. The recommendation concerns the treatment of adults with insufficiently controlled type 2 diabetes. Kyinsu is used alongside diet, exercise and oral diabetes medicines, according to a Friday note. The indication previously allowed the use of the drug in type 2 diabetes patients whose condition was inadequately controlled with basal insulin or glucagon-like peptide-1 receptor agonists. The indication changes are subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.